Introduction {#Sec1}
============

Intracranial large artery stenosis (ILAS) is a leading cause of ischemic stroke, especially for Asians and Africans \[[@CR1], [@CR2]\]. Several large clinical trials \[[@CR3]--[@CR9]\] have focused on treating intracranial stenosis in which stenosis severity was used to guide treatment decisions. However, most of these trials failed to demonstrate the superior benefits of these treatments to reduce recurrent stroke in patients with ILAS, and the stenting treatment was not better than aggressive medical treatment for preventing recurrent stroke \[[@CR10]\]. In addition, the WASID trial and other clinical findings pointed out that risk factors play important roles in reducing the recurrence of stroke or vascular events \[[@CR5], [@CR11]--[@CR13]\]. Given these results, the role of stenosis for unfavorable outcomes is still uncertain. The need to re-identify factors for these outcomes in community-dwelling patients with ILAS is warranted.

These aforementioned studies were limited by patient selection bias (patients coming from clinical trials), no comparable control groups (no recruitment of patients without stenosis), and only consideration of stenosis without inclusion of possible risk factors \[[@CR13]\]. Only one study recruited community-based participants to investigate the characteristics and outcomes of patients with vs without ILAS \[[@CR2]\]. Controversial evidence for the need to treat asymptomatic ILAS to reduce the risk of an unfavorable outcome was recently reported \[[@CR14], [@CR15]\]. The significance of asymptomatic ILAS awaits further investigation.

The primary aim of this study was to examine how the status of ILAS and risk factors in patients with ischemic stroke affect unfavorable outcomes after medical treatment in routine clinical practice. ILAS status was categorized as patients with ILAS vs without ILAS. Patients with ILAS were further divided into the subgroups of patients with asymptomatic vs symptomatic ILAS.

Methods {#Sec2}
=======

Study design and participants {#Sec3}
-----------------------------

This was a 24-month prospective observational single hospital-based study that consecutively recruited ischemic stroke patients. The study enrolled patients who met all of the following eligibility criteria: (1) patients with acute ischemic stroke or transient ischemic attack; (2) patients without intracerebral hemorrhage; (3) patients who had received magnetic resonance (MR) imaging (MRI)/MR angiography (MRA) screening in the acute hospitalization; and (4) patients who provided written informed consent. The institutional review board of the Chang Gung Memorial Hospital at Kaohsiung Medical Center approved the study protocols \[[@CR16]\].

Assessment of patient characteristics {#Sec4}
-------------------------------------

Demographic and clinical characteristics were assessed. The risk factors included body mass index (BMI), internal carotid artery (ICA) stenosis, glomerular filtration rate (GFR), serum uric acid level, baseline neurologic deficits, and history of ischemic stroke, hypertension, diabetes mellitus (DM), hyperlipidemia, heart disease (congestive heart failure, valvular heart disease, and history of cardiac disease), atrial fibrillation, and smoking \[[@CR17]\]. Clearer exclusion criteria or classification criteria and corresponding analysis may eliminate those biases. A BMI of ≥27 kg/m^2^ was categorized as indicating obesity and 24 to 27 kg/m^2^ as overweight. ICA stenosis was classified as \> 50% and ≤ 50%. ICA was evaluated by carotid duplex imaging during the acute hospitalization, with stenosis \> 50% defined as a peak systolic velocity ≥ 140 cm/s or as a ratio of the ICA peak systolic velocity to the common carotid artery peak systolic velocity of \> 2 \[[@CR18]\]. A neurologist evaluated the ICA ratings. Three investigators discussed and decided the ratings together when the quality of the carotid duplex images was suboptimal. The creatinine clearance rate was estimated using the Cockcroft-Gault formula. GFR \< 60 mL/min/1.73 m^2^ was assessed as abnormal, and results were further categorized into two groups with above or below 30 mL/min/1.73 m^2^. A serum uric acid level of \> 8.3 mg/dL was assessed as abnormal.

Baseline neurologic deficits at admission were assessed with National Institutes of Health Stroke Scale (NIHSS), with a scale from 0 to 38 (0 = normal). In addition, the stroke etiology (the subtype of recurrent stroke) might have a large effect on the outcome of recurrent stroke; thus, the subtype of recurrent stroke was further classified into small vessels occlusive, cardioembolism, and atherosclerosis.

Image analysis/participant classification {#Sec5}
-----------------------------------------

All participants underwent MRA on a 1.5-T MR scanner (the Philips Gyroscan Intera or the GE Signa). Although MRA 3 T is available and outperformed MRA 1.5 T in various outcomes, such as improved signal-to-noise ratio and higher resolution, its use is usually limited to the research setting. However, MRA 1.5 T is routinely used in clinics and is easily accessible to scan a large number of patients. Three-dimension time of flight was used. The image was usually reconstructed from 80 images insonated centered at the sella and 19 images from the sagittal plane. Brain MRA was used to assess 13 segments of intracranial large arteries: bilateral intracranial ICA, first and second part of the middle cerebral arteries, anterior cerebral arteries, posterior cerebral arteries, vertebral arteries, and basilar artery. Because the criteria used for stenosis evaluation on a cerebral angiogram are not easily adapted for MRA, a modified method to clarify ILAS was explored \[[@CR3], [@CR19], [@CR20]\]. In this study, source and maximum intensity projection images were both available for MRA. The single view with the highest percentage of stenosis was measured. Four-scale grading of ILAS severity was developed by the study team: (1) mild: no obliteration of flow of a vessel, (2) moderate: obliteration of flow between two segments of a vessel, (3) severe: flow void between two segments of a vessel, and, (4) occlusion: no flow after a specific point of a vessel.

For descriptive purpose, we categorized patients as patients without ILAS (ILAS--), including the mild group, and patients with ILAS (ILAS+), including moderate, severe, and occlusion groups. ILAS+ was further categorized into two groups: symptomatic ILAS+ (ILAS+S), defined as ILAS with corresponding acute infarct detected by an MRI diffusion-weighted image or clinical symptoms, regardless the presence or absence of asymptomatic ILAS+ (ILAS+AS), and ILAS+AS as ILAS coexisting with no corresponding infarction. The number of ILAS+ was classified as single if only one stenotic segment was recognized and as multiple if more than one stenotic segment was found.

The ILAS in this study was documented by board-certified neuroradiologists unaware of the patients' recruitment status. After recruitment was completed, one neurologist blinded to the outcomes of patients confirmed the stenosis ratings. If no focal stenosis was identified, although smaller in caliber compared with the other side, the vessel would be assessed as no ILAS \[[@CR20], [@CR21]\]. If the quality of images from MRI/MRA was suboptimal, a panel of three investigators decided the grading. Old infarction identified by brain MRI was reported by neuroradiologists and retrospectively confirmed by one investigator without information on the clinical presentation.

Assessment of outcome events {#Sec6}
----------------------------

Because of the universal health insurance program in the study area with a single payer and limited copayment, MRI use was not confounded by socioeconomic status \[[@CR21], [@CR22]\]. Approximately 70% of admitted patients with ischemic stroke in this study hospital would have undergone brain MRI, including MRA, in the acute hospitalization. After acute hospitalization, patients usually visited clinics every 1 to 3 months for prescriptions to control risk factors and for stroke prevention. Therapies to prevent vascular events were similar to prophylactic medical or surgical therapies used for high-risk patients. Concomitant medication data were not collected in detail, but the inequality of care related to the incidence of outcome events was carefully checked. To address efficacy of care, we categorized patients as monitored in the study hospital or other care facilities and categorized risk factors as regularly treated, irregularly treated, or not treated. The scheduled visits of this observational study were every 6 months after enrollment by investigators. All patients were to be monitored until death or the end of the study.

The outcome events were (1) vascular outcome events, defined as cerebrovascular with recurrent stroke; cardiovascular event as any cardiovascular diseases requiring revascularization or admission; renovascular event as serum creatinine level increased by two times during follow-up, newly initiated hemodialysis, or diagnosis of nephropathy; or other vascular disease with vascular entity-related diagnosis at any new admission or emergency department visits, at the discretion of the investigators; (2) recurrent stroke, defined as an ischemic or hemorrhagic stroke after the first index stroke during the follow-up period; and (3) death. Outcome events were verified by hospital records and ascertained by one neurologist.

Statistical analysis {#Sec7}
--------------------

SPSS 16.0 software (SPSS Inc., Chicago, IL, USA) was used for data analyses. The χ^2^ test was used to determine significant differences in attributes studied in relation to ILAS. Cox regression was used to assess how ILAS+ symptomatic/asymptomatic and risk factors affected unfavorable outcome events. The variables included in the Cox regression analysis were sex, BMI, ICA stenosis, GFR, serum uric acid level, baseline neurologic deficits, and history of ischemic stroke, hypertension, DM, hyperlipidemia, heart disease, atrial fibrillation, smoking, multiple stenosis, and stenosis status. In the Cox regression, variables of interest were backward selected in the models. We further performed univariate analysis using the etiologic classification as the potential predictor of recurrent stroke and also multivariate Cox regression analysis involving the other variables together with the variable of stroke etiology as the potential predictors. All significant tests were two-tailed, and differences were considered to be statistically significant at a *p* \< .05 level.

Results {#Sec8}
=======

The study recruited 686 patients \[Fig. [1](#Fig1){ref-type="fig"}\]; among these, 315 (45.9%) were assessed as ILAS+ and 371 (54.1%) as ILAS−, and among the ILAS+ patients, 231 (33.7%) were assessed as ILAS+S and 84 (12.2%) as ILAS+AS. Vessel occlusions were documented in 63 patients. The brain MRI was done 4.5 ± 5.6 days after stroke onset. Throughout the study, modifiable risk factors were regularly treated in 213 ILAS+S (92.2%), 78 ILAS+AS (92.9%), and 344 ILAS− (92.7%) patients. All participants were monitored for 1.1 (standard deviation, 0.6) years on average. During this period, 91 participants had a vascular outcome, 57 participants had a recurrent stroke, and 51 participants died.Fig. 1Recruitment and follow-up flowchart

The baseline characteristics of the participants in the ILAS+S, ILAS+AS, and ILAS− groups are summarized in Table [1](#Tab1){ref-type="table"}. There were significant differences among the three groups in the incidences of extracranial carotid artery stenosis \> 50% and baseline NIHSS scores. History of previous stroke was documented by medical history in 34.5 to 41.6% of patients, and an old infarction was evident by brain MRI in 66.7 to 79.8% of patients. No significant differences were found among the three groups on treatment frequency of risk factors, indicating that control of risk factors during the study period might not be a confounder.Table 1Characteristics of 686 patients enrolledTotal (*N* = 686)ILAS+S (*n* = 231, 33.7%)ILAS+AS (*n* = 84, 12.2%)ILAS-(*n* = 371, 54.1%)*P*N(%)N(%)N(%)Age, y  \< 6526582(35.5)42(50)141(38)0.061  ≥ 65421149(64.5)42(50)230(62)Sex Female25088(38.1)34(40.5)128(34.5)0.48 Male436143(61.9)50(59.5)243(65.5)Body mass index, kg/m^2^0.624  \< 24306101(43.7)44(52.4)161(43.4)0.514 24--2723081(35.1)24(28.6)125(33.7)  ≥ 2715049(21.2)16(19.)85(22.9)Carotid artery stenosis  \< 50%602180(85.7)72(91.1)350(96.7)\< 0.001  ≥ 50%4930(14.3)7(8.9)12(3.3)Glomerular filtration rate  ≥ 60345103(44.6)45(53.6)197(53.2)0.084 30--59285113(48.9)33(39.3)139(37.6)  \< 305515(6.5)6(7.1)34(9.2)Uric acid5.9±4.45.9±1.95.6±1.80.36 Normal597190(86.4)72(86.7)335(91.5)0.109 Abnormal7230(13.6)11(13.3)31(8.5)History of ischemic stroke25496(41.6)30(35.7)128(34.5)0.211Hypertension481170(73.6)66(78.6)245(66)0.028Diabetes mellitus27794(40.7)42(50)141(38)0.128Hyperlipidemia386144(62.3)47(56)195(52.6)0.063Heart disease17162(26.8)21(25)88(23.7)0.69Atrial fibrillation5017(7.4)8(9.5)25(6.7)0.674Smoking23883(35.9)24(28.6)131(335.3)0.448Baseline NIHSS 0--6413120(51.9)55(65.5)238(64.2)\< 0.001 7--1519866(28.6)20(23.8)112(30.2) 16--387545(19.5)9(10.7)21(5.7)Old infarction480154(66.7)67(79.8)259(69.8)0.081Multiple ILAS185144(62.3)41(48.8)0(0)Risk factors control treatment Regular treated635213(92.2)78(92.9)344(92.7)0.997 Not treated4014(6.1)5(6.0)21(5.7) Irregular114(1.7)1(1.2)6(1.6)Follow Follow-up in the study hospital587189(86.5)77(91.7)321(81.8)0.066 Follow-in other care facilities9942(13.5)7(8.3)50(18.2)§ *ILAS* Intracranial Large Artery Stenosis, *ILAS+S* symptomatic ILAS, *ILAS+AS* asymptomatic ILAS, *NIHSS* National Institutes of Health Stroke Scale

Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} report hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for outcome events by characteristics of the patients. Significant factors in the univariate analysis associated with the vascular outcome were GFR, hypertension, heart disease, and old infarction. The multivariate analysis demonstrated a BMI of 24 to 27 kg/m^2^ (HR, 0.59; 95% CI, 0.35 to 0.97; *p* = .039) and \> 27 kg/m^2^ (HR, 0.55; 95% CI, 0.30 to 1.00; *p* = .049), hypertension (HR, 2.18; 95% CI, 1.20 to 3.94; *p* = .01), and old infarction (HR, 1.74; 95% CI, 1. 01 to 2.99; *p* = .047) were factors relating to the vascular outcome \[Table [3](#Tab3){ref-type="table"}\]. However, the univariate and multivariate analysis showed hypertension was the only factor (HR, 2.20; 95% CI, 1.06 to 4.58; *p* = .035) accounting for the recurrent stroke. For death, the univariate analysis showed sex, GFR, uric acid, DM, heart disease, atrial fibrillation, and baseline neurologic deficits were significant factors, and the multivariate analysis showed poor GFR (\< 30 mL/min/1.73 m^2^; HR, 3.79; 95% CI, 1.36 to 10.6; *p* = .011) and poor baseline NIHSS scores (\> 16; HR, 9.98; 95% CI, 4.35 to 22.91; *p* \< .001) were significant.Table 2Predictors of vascular outcome, recurrent stroke, and death in 686 patients (univariate analysis)Vascular outcomeRecurrent strokeDeathHazard Ratio (95%CI)*P* ValueHazard Ratio (95%CI)*P* ValueHazard Ratio (95%CI)*P* ValueAge, y  ≤ 64111  ≥ 651.169(.762--1.792).4741.140(.666--1.953).6331.449(.802--2.618).219Sex Female111 Male1.026(.667--1.578).9071.218(.697--2.129).490.526(.304--.912).022Body mass index, kg/m^2^  \< 24111 24--27.740(.464--1.179).205.820(.453--1.482).511.800(.438--1.461).467  ≥ 27.600(.336--1.071).084.762(.379--1.530).444.418(.173--1.008).052Carotid artery stenosis  ≤ 50%111  \> 50%1.072(.495--2.320)0.8601.488(.638--3.470)0.3580.044(0--6.445).220Glomerular filtration rate  ≥ 60111 30--591.305(.840--2.029).2371.171(.683--2.008)0.5671.956(1.039--3.684).038  \< 302.181(1.117--4.258).0221.048(.367--2.992)0.9314.958(2.298--10.695)\<.001Uric acid Normal111 Abnormal1.583(.879--2.851).1261.495(.707--3.160).2932.269(1.132--4.545).021Hypertension2.094(1.203--3.642).0092.187(1.073--4.457).0311.178(.628--2.212).610Diabetes mellitus1.375(.912--2.075).1291.231(.731--2.073).4351.753(1.010--3.044.046Hyperlipidemia1.023(.675--1.550).9141.141(.672--1.937).625.861(.497--1.492).594Heart disease1.678(1.095--2.574).0181.143(.641--2.037).6512.226(1.279--3.875).005Atrial fibrillation1.466(.709--3.033).302.512(.125--2.102).3532.345(1.055--5.213).036Smoking.923(.600--1.420).715.942(.547--1.625).831.540(.282--1.031).062Baseline NIHSS 0--6111 7--15.766(.411--1.428).401.754(.395--1.440).3922.709(1.306--5.620).007 16--38.765(.379--1.547).456.774(.305--1.961).58810.003(5.116--19.561)\<.001Old infarction1.804(1.087--2.992).0221.572(.846--2.921).1521.843(.923--3.680).083Stenosis state ILAS-111 ILAS+AS1.657(.951--2.886).0751.370(.622--3.018).4352.115(.996--4.963).051 ILAS+S.977(.608--1.568).9221.384(.788--2.431).2581.585(.895--2.924).141Multiple stenosis1.213(.773--1.901).4011.224(.694--2.158).4861.555(.875--2.761).132Subtypes of stroke Small vessel occlusive--1.595-- Atherosclerosis------.483(.035--6.636).587------ Cardioembolism------.909(.075--11.027).941------§ *ILAS* Intracranial Large Artery Stenosis, *ILAS+S* symptomatic ILAS, *ILAS+AS* asymptomatic ILAS, *NIHSS* National Institutes of Health Stroke ScaleTable 3Multivariate Cox proportional-hazard regression analysis for vascular outcome, recurrent stroke, and death (*N* = 685)Vascular outcomeRecurrent strokeDeathHazard Ratio (95%CI)*P* ValueHazard Ratio (95%CI)*P* ValueHazard Ratio (95%CI)*P* ValueAge, y  ≤ 64--------  ≥ 65--------Sex Female1----1 Male1.146(.685--1.918).605----.681.311--1.492.337Body mass index, kg/m^2^  \< 241------ 24--27.587(.354--.974).039------  ≥ 27.550(.303--.997).049------Carotid artery stenosis  ≤ 50%--------  \> 50%--------Glomerular filtration rate  ≥ 60------1 30--59------1.965.875--4.415.102  \< 30------3.7931.357--10.596.011Uric acid Normal1----1 Abnormal1.697(.881--3.271).114----2.021.842--4.854.115Hypertension2.176(1.202--3.939).0102.200(1.058--4.576).035--Diabetes mellitus--------Hyperlipidemia--------Heart disease--------Atrial fibrillation--------Smoking.773(.460--1.300).332.701(.374--1.315).269--Baseline NIHSS 0--61----1 7--15.936(.551--1.589).806----2.011.898--4.504.089 16--381.438(.711--2.908).312----9.9784.345--22.914\<.001Old infarction1.735(1.008--2.987).047----1.393.560--3.465.476Stenosis state ILAS-1----1 ILAS+AS1.180(.650--2.139).587----1.644.688--4.048.280 ILAS+S.842(.506--1.402).508----.886.408--1.927.760Multiple stenosis--------Subtypes of stroke Small vessel occlusive-------- Atherosclerosis---------------- Cardioembolism----------------§ *ILAS* Intracranial Large Artery Stenosis, *ILAS+S* symptomatic ILAS, *ILAS+AS* asymptomatic ILAS, *NIHSS* National Institutes of Health Stroke Scale

Discussion {#Sec9}
==========

To date, the optimal treatment of ILAS has not been confirmed \[[@CR23]\]. The current study attempted to identify the role of stenosis, in addition to risk factors, for unfavorable outcomes in an effort to augment treatment efficacy. This study with stroke patients outside the clinical trial settings demonstrated that the risk factors, but not the status of stenosis, were the most significant predictors for unfavorable outcome events after medical treatment rather than the stenosis status. The current data suggested that aggressively controlling risk factors might be a prerequisite for preventing adverse outcome events in patients with stroke.

The results of this study indicate that risk factors were associated with worsening disease activity. Consistent with previous studies \[[@CR3], [@CR12], [@CR24]--[@CR28]\], our study provided data supporting the need to control risk factors in patients with ILAS. The findings showed that hypertension was one of the factors relating to vascular outcome events and the independent factor to recurrent stroke. In general, hypertension may stiffen arteries and progress artery disease, possibly relating to an increased risk of vascular events and recurrent stroke. Old infarction and BMI, along with hypertension, were related to vascular outcome events. Overweight (BMI, 24--27 kg/m^2^) and obese (BMI ≥ 27 kg/m^2^) patients have a lower incidence of vascular outcome events than patients with a BMI of \< 24 kg/m^2^. Orpana et al. \[[@CR29]\] suggested that being overweight (BMI, 25--29.9 kg/m^2^) has a significant protective effect for all-cause mortality compared with being underweight (BMI, 18.5 kg/m^2^). A scrutiny of our data showed that half of our obese patients had a BMI of 27 to 30 kg/m^2^. The protective nature associated with a low incidence of undesirable outcomes may have merit in the overweight and obese patients in this study.

GFR, uric acid, and baseline neurologic deficits (NIHSS admission score) were factors relating to death outcomes in our study. Chronic kidney disease may trigger vascular damage and endothelial dysfunction \[[@CR30]\], and previous studies indentified renal dysfunction or chronic kidney disease as strong risk factors of stroke \[[@CR26], [@CR27], [@CR30]\]. This study further suggested that renal dysfunction or chronic kidney disease in patients with cerebrovascular disease may be relevant to death. Patients with severe neurologic impairments, as represented by an NIHSS score \> 15, have higher incidence of an adverse outcome than those with mild impairments; therefore, the NIHSS score could provide prognostic information to patients and clinicians.

Concurrently considering other relevant characteristics relating to the outcome events, neither ILAS+ and ILAS-- nor ILAS+S and ILAS+AS were significant predictors for unfavorable outcome events. Thus, the presence or absence of stenosis and the presence of asymptomatic or symptomatic stenosis were not prominent factors for the outcome events. Although our finding is counterintuitive with the long-standing assumption that stenosis severity is an indicator for treatment decisions to reduce adverse outcome, it reinforces observations from the recent clinical trial that the degree of stenosis does not predict an adverse outcome after treatment with intracranial stents \[[@CR10]\]. Our results extend the results from clinical trials with only patients with symptomatic stenosis to a community-based cohort study with patients with symptomatic and asymptomatic stenosis. The reason for stenosis being a non-significant predictor might be that the pathophysiologic mechanisms of recurrent stroke or adverse events in patients with intracranial stenosis are attenuated over time \[[@CR6], [@CR31]--[@CR33]\].

However, our finding is inconsistent with the previous cohort study \[[@CR3]\] that occlusion was a significant predictor. The differences between these two studies are in the criterion for recurrent stroke and the classification of stenosis. The previous study included recurrent stroke, targeting only at the territory of the stenotic artery, whereas the present study included all types of recurrent stroke. Furthermore, the present study did not dichotomize lesions with stenosis vs occlusion or near occlusion, whereas the previous study did. We argued that the differentiation between these two is arbitrary and that the accuracy might be questionable \[[@CR2]\]. In light of these results, an alternative to lesion stratification according to stenosis might be considered. For example, hypoperfusion vs non-hypoperfusion symptoms \[[@CR11]\] or intracranial plaque vs plaque-negative stenosis \[[@CR13]\] might deserve further investigation for their possible roles in relating to adverse outcome.

That the participants in this study did not come from clinical trials is noteworthy. They were not population-based but from a metropolitan medical center. However, the incidence of carotid artery stenosis identified by duplex as \> 50% was 3 to 14% and higher in patients with ILAS (ILAS+S and ILAS+AS), which was compatible with the incidence reported in the previous study using population-based data \[[@CR18]\], indicating the data obtained in the present study should be representative of the general stroke population.

The incidence of patients with ILAS+S and ILAS+AS in this study was similar to the previous study \[[@CR2]\], which might be as expected in the Asian population, where the burden of stroke is tremendous. Brain MRI identified an old infarction in \> 60% of the study patients, which is higher than the incidence of medical history of ischemic stroke of 33.8 to 41.2%. It might be that patients the present study underwent vascular screening using MRI, whereas the history of previous stroke was documented by computed tomography screening. MRI is more sensitive than computed tomography for detecting ischemic injury, which made the high incidence of old infarction found in the present study acceptable. To avoid overestimation of ILAS by MRA, the visual-based grading of severity of ILAS in this study was modified from the previous design \[[@CR3], [@CR19]\] and might be compatible with the methods used in acute stroke trials \[[@CR6]\].

Our study has limitations. First, our study was subject to bias because participants were recruited in one medical center. However, the study hospital is the main referral hospital for all types of stroke in the Kaohsiung metropolitan area of Taiwan. The incidence of carotid artery stenosis in the present study was compatible with the incidence reported in the previous study using population-based data, suggesting the data are representative of the population scenario.

Second, owing to limited research manpower, detailed information on concomitant medication or modification of risk factor control is lacking, which might have introduced errors in the analysis of the incidence of outcome events. However, we attempted to reduce such bias in terms of reporting that patients had high rates of being monitored in the study hospital and of being treated for risk factors.

Third, there is no universally accepted standard to diagnose ILAS. In this study, we used MRA and explored a modified method to clarify the stenosis of ILAS based on the study by Chimowitz et al. \[[@CR3]\], which should be arguably acceptable.

Fourth, there are several imaging modalities, such as MRA, computed tomographic angiography (CTA), and digital subtraction angiography (DSA), can be used to assess intracranial stenosis, we used MRA to identify ILAS instead of DSA and CTA, which are more sensitive. DSA is considered the gold standard for diagnosing intracranial vascular diseases, and CTA may provide higher diagnostic accuracy of the intracranial atherosclerosis than MRA \[[@CR34]\]. DSA, however, can cause some complications, such as transient neurologic deficits \[[@CR34]\]. CTA may expose patients to high radiation doses, and the probability of cancer and other biological effects is increased \[[@CR35]\]. MRA does not emit damaging ionizing radiation, so that patients are not exposed to these harmful effects. Owing to practical considerations and feasibility, we chose MRA to identify ILAS.

Fifth, some factors that might influence the incidence of outcomes, such as lesion stability, were not included. We recommend that future studies consider these factors.

Conclusions {#Sec10}
===========

This study extended previous results from clinical trials to a community-based cohort study concurrently investigating the presence/absence of stenosis, symptomatic/asymptomatic stenotic artery, and substantial risk factors. Hypertension, BMI, and renal dysfunction status are among the substantial risk factors that are predominant determinants of an adverse outcome rather than the stenosis. We suggest that although the degree of stenosis is often an indicator for treatment, risk factors should be monitored and intensively treated. Future research might consider other classification systems, such as perfusion symptoms or features of the plaque, instead of the type of stenosis, as potential factors of predicting adverse outcome.
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